ELAPOR2

Across TCGA pan-cancer cohorts, ELAPOR2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ELAPOR2 data layer compared with 23 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ELAPOR2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ELAPOR2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and GBM show a favorable association.

CCRCC, LUAD, and PDAC are the cancer types where ELAPOR2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	IV	0.105	0.859	.008	33	view →
LUAD	DFS	Tertile	All	1.000	0.470	.006	11	view →
PDAC	OS	Quartile	III,IV	0.348	0.901	.024	5	view →
HNSC	DFS	Median	All	0.537	0.777	.024	4	view →
GBM	DFS	Median	All	0.449	0.289	.023	2	view →
LSCC	OS	Median	All	1.000	0.813	.037	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ELAPOR2–CCRCC (OS)

Open the CCRCC breakdown →